The ubiquitin protein catabolic disorders

Neuropathology and Applied Neurobiology

Volumn 27, Issue 3, 2001, Pages 171-179

  Layfield, Robert ^a   Alban, Andrew ^a   John Mayer, R ^a   Lowe, James ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Alzheimer's disease; Neurodegeneration; Proteasome; Ubiquitin

Indexed keywords

PROTEASOME; UBIQUITIN; UBIQUITIN PROTEIN LIGASE;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; GENE MUTATION; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN PROCESSING; REVIEW;

ALZHEIMER DISEASE; CYSTEINE ENDOPEPTIDASES; HUMANS; INCLUSION BODIES; METABOLIC DISEASES; MULTIENZYME COMPLEXES; MUTATION; NEURONS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; UBIQUITINS;

EID: 0034918873     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2990.2001.00335.x     Document Type: Review

References (54)

1. In vivo disassembly of free poly-ubiquitin chains by yeast Ubp14 modulates rates of protein degradation by the proteasome
2. Alphasynuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells
3. Mdm2 expression is induced by wild type p53 activity
4. Degradation of alpha-synuclein by proteasome
5. Accelerated in vitro fibril formation by a mutant alpha synuclein linked to early-onset Parkinson disease
6. C-terminal maturation fragments of presenilin 1 and 2 control secretion of APP alpha and A beta by human cells and are degraded by proteasome
7. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
8. Neurofibrillary tangles in progressive supranuclear palsy brains exhibit immunoreactivity to frameshift mutant ubiquitin-B protein
9. Amyloid, the presenilins and Alzheimer's disease
10. Autosomal recessive juvenile parkinsonism; a key to understanding nigral degeneration in sporadic Parkinson's disease
11. The ubiquitin system
12. Siah-1 N-terminal RING domain is required for proteolysis function, and C-terminal sequences regulate oligomerization and binding to target proteins
13. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity
14. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin-ligase complex
15. Motor neurone disease-inclusion dementia
16. Aggresomes: A cellular response to misfolded proteins
17. Protein precipitation: A common etiology in neurodegenerative disorders?
18. Huntingtin is ubiquitinated and interacts with a specific ubiquitin conjugating enzyme
19. Impaired proteasome function in Alzheimer's disease
20. UBE3A/E6-AP mutations cause Angelman syndrome
21. Mutations in the parkin gene cause autosomal recessive juvenile Parkinsonism
22. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease
23. The latent membrane protein-1 in Epstein-Barr virus-transformed lymphoblastoid cells is found with ubiquitin-protein conjugates and heat-shock protein 70 in lysosomes oriented around the microtubule organizing centre
24. Does an inhibition of the ubiquitin/26S proteasome pathway of protein degradation underlie the pathogenesis of non-familial Alzheimer's disease?
25. The ubiquitin pathway in Parkinson's disease
26. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity
27. Defective ubiquitination of cerebral proteins in Alzheimer's disease
28. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination
29. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease
30. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases
31. Alpha B crystallin expression in non-lenticular tissues and selective presence in ubiquitinated inclusion bodies in human disease
32. Ubiquitin in neurodegenerative diseases
33. Proteasomal function is impaired in substantia nigra in Parkinson's disease
34. Lessons from keratin 18 knockout mice: Formation of novel keratin filaments, secondary loss of keratin 7 and accumulation of liver-specific keratin 8-positive aggregates
35. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome
36. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments
37. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: The loss of wild-type p53 function and the hsp90 association
38. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease
39. Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo
40. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice
41. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions
42. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
43. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
44. Nuclear inclusions in glutamine repeat disorders: Are they pernicious, coincidental, or beneficial?
45. Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: Genes associated with familial Parkinson's disease
46. Alpha synuclein in Lewy bodies
47. Tau gene mutations in frontotempoal dementia and Parkinsonism linked to chromosome 17 (FTDP-17)
48. Recognition of the polyubiquitin proteolytic signal
49. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients
50. Molecular misreading in non-neuronal cells
51. Degradation of CFTR by the ubiquitin-proteasome pathway
52. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease
53. Proteasomal degradation and N-terminal protease resistance of the codon 145 mutant prion protein
54. Presenilins are required for gamma-secretase cleavage of beta-APP and transmembrane cleavage of Notch-1